Dong-A ST creates antidiabetic agent combining ‘Suganon-Actos’

Published: 2016-01-19 10:59:05

Updated: 2016-01-19 10:59:05

Dong-A ST has started to develop a complex combining Suganon(evogliptin), a domestic DPP-4-inhibitor treatment, and Actos(pioglitazone, Takeda Pharmaceutical), a TZD-type drug.

The Ministry of Food and Drug Safety approved the Phase 1 clinical trial of a complex combining evogliptin 5mg and pioglitazone 30mg, applied by Dong-A ST.

According to the contents of the approval on the 17^th, the cli...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.